Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma

Volume: 28, Pages: 101310 - 101310
Published: Jan 1, 2020
Abstract
Multiple myeloma (MM), the second most common haematological malignancy, is a clonal plasma B-cell neoplasm that forms within the bone marrow. Despite recent advancements in treatment, MM remains an incurable disease. Auranofin, a linear gold(I) phosphine compound, has previously been shown to exert a significant anti-myeloma activity by inhibiting thioredoxin reductase (TrxR) activity. A bis-chelated tetrahedral gold(I) phosphine complex...
Paper Details
Title
Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma
Published Date
Jan 1, 2020
Volume
28
Pages
101310 - 101310
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.